107.59

5.57% -6.1547

Rhythm Pharmaceuticals Inc (RYTM)

Overview News Price History Option Chain Financials Discussions Forecast

Rhythm Pharmaceuticals Inc stock is traded at $107.59, with a volume of 606.30K. It is down -5.57% in the last 24 hours and up +8.47% over the past month. Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

Previous Close:

$113.74

Open:

$102.46

24h Volume:

606.30K

Relative Volume:

1.01

Market Cap:

$7.13B

Revenue:

$136.86M

Net Income/Loss:

$-168.69M

P/E Ratio:

-38.29

EPS:

-2.81

Net Cash Flow:

$-113.49M

1W Performance:

-5.34%

1M Performance:

+8.47%

6M Performance:

+67.79%

1Y Performance:

+102.69%

1-Day Range:

$102.10

$112.66

1-Week Range:

$102.10

$116.00

52-Week Range:

$45.91

$116.00

Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile

Name

Rhythm Pharmaceuticals Inc

Sector

Healthcare (1140)

Industry

Biotechnology (633)

Phone

857-264-4280

Address

222 BERKELEY STREET, BOSTON, MA

Employee

283

Twitter

@rhythmpharma

Next Earnings Date

2024-11-05

Latest SEC Filings

RYTM's Discussions on Twitter

Compare RYTM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RYTM Rhythm Pharmaceuticals Inc	107.39	7.55B	136.86M	-168.69M	-113.49M	-2.81
VRTX Vertex Pharmaceuticals Inc	424.67	109.22B	11.39B	3.64B	3.50B	13.99
REGN Regeneron Pharmaceuticals Inc	631.49	67.50B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	425.97	57.35B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	838.79	50.87B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	184.66	39.72B	447.02M	-1.18B	-868.57M	-6.1812

Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Initiated	Goldman	Buy
Jul-07-25	Initiated	Leerink Partners	Outperform
Apr-07-25	Upgrade	BofA Securities	Neutral → Buy
Mar-05-25	Resumed	Stifel	Buy
Jan-02-25	Initiated	Jefferies	Buy
Dec-20-24	Initiated	Oppenheimer	Outperform
Oct-21-24	Initiated	Guggenheim	Buy
Sep-18-24	Initiated	H.C. Wainwright	Buy
Sep-17-24	Initiated	JMP Securities	Mkt Outperform
May-08-24	Downgrade	BofA Securities	Buy → Neutral
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-01-23	Upgrade	BofA Securities	Neutral → Buy
Jan-18-23	Resumed	Canaccord Genuity	Buy
Aug-08-22	Upgrade	Goldman	Neutral → Buy
Aug-05-22	Upgrade	BofA Securities	Underperform → Neutral
Jun-17-22	Reiterated	Needham	Buy
Mar-02-22	Resumed	Stifel	Buy
Feb-17-22	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-19-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-14-21	Resumed	Goldman	Neutral
Aug-04-21	Downgrade	BofA Securities	Neutral → Underperform
Aug-04-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Nov-30-20	Downgrade	BofA Securities	Buy → Neutral
Jan-08-20	Initiated	Goldman	Sell
Jul-12-19	Upgrade	Stifel	Hold → Buy
Jul-08-19	Initiated	Canaccord Genuity	Buy
Mar-13-19	Initiated	Ladenburg Thalmann	Buy
Sep-07-18	Resumed	Morgan Stanley	Overweight
Jun-25-18	Reiterated	Needham	Buy
Jun-15-18	Reiterated	Needham	Buy
Oct-30-17	Initiated	BofA/Merrill	Buy
Oct-30-17	Initiated	Needham	Buy

View All

Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News

12:37 PM

Needham Raises Price Target for RYTM to $122, Maintains Buy Rati - GuruFocus

12:37 PM

08:15 AM